BALTIMORE, MD – May 7, 2019 — Greater Cannabis Company (OTC: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced it has entered into a letter of agreement (LOI) with European-based Symtomax, a licensed group on medical cannabis cultivation, research and distribution with over 40 years of experience in the medical cannabis industry. Effective immediately, Symtomax will distribute on a white-label basis ...
Read More

In the next five years, Europe is set to become the world’s largest legal cannabis market. With a population of more than double that of the United States and Canada combined, the market is ripe, and the industry has grown more in the last year than the last six combined, according to a new report. ...
Read More

Symtomax have submitted their application for licenses to cultivate, manufacture, distribute, import and export medical cannabis. Chairman of the Symtomax Group Paul Segal commented “this marks a very exciting time for Symtomax, having performed some very in depth feasibility studies; Portugal was the clear leader in our expansion plans. Not only does it offer an ideal climate for growing, it has a reputable agricultural and well developed transport infrastructure, together ...
Read More